Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HUTCHMED (China) ( (HK:0013) ) just unveiled an announcement.
HUTCHMED has completed patient enrollment for the SANOVO Phase III trial in China, testing the combination of ORPATHYS® and TAGRISSO® as a first-line treatment for certain non-small cell lung cancer patients. This trial aims to assess the efficacy and safety of the drug combination compared to TAGRISSO® alone, with results expected in the second half of 2026. Successful outcomes could lead to a new drug application in China, potentially enhancing HUTCHMED’s market position in the oncology sector.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company collaborates with AstraZeneca to commercialize its products, with a market focus on China and other global markets.
Average Trading Volume: 10,767,289
Technical Sentiment Signal: Hold
Current Market Cap: HK$22.41B
See more data about 0013 stock on TipRanks’ Stock Analysis page.